Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Assets Average (2018 - 2025)

Historic Assets Average for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to $36.2 million.

  • Cue Biopharma's Assets Average fell 1697.06% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.2 million, marking a year-over-year decrease of 1697.06%. This contributed to the annual value of $46.9 million for FY2024, which is 3866.95% down from last year.
  • Latest data reveals that Cue Biopharma reported Assets Average of $36.2 million as of Q3 2025, which was down 1697.06% from $31.5 million recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Assets Average peaked at $94.1 million during Q1 2021, and registered a low of $27.2 million during Q1 2025.
  • For the 5-year period, Cue Biopharma's Assets Average averaged around $66.9 million, with its median value being $77.4 million (2023).
  • As far as peak fluctuations go, Cue Biopharma's Assets Average surged by 4234.34% in 2021, and later plummeted by 5285.37% in 2025.
  • Over the past 5 years, Cue Biopharma's Assets Average (Quarter) stood at $81.1 million in 2021, then increased by 3.27% to $83.8 million in 2022, then decreased by 22.18% to $65.2 million in 2023, then crashed by 40.96% to $38.5 million in 2024, then fell by 6.04% to $36.2 million in 2025.
  • Its Assets Average stands at $36.2 million for Q3 2025, versus $31.5 million for Q2 2025 and $27.2 million for Q1 2025.